Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Luspatercept in Preventing Poor Erythroid Engraftment After Allo-HSCT for Hematological Malignancies With Moderate to Severe Myelofibrosis: A Prospective, Multicenter, Randomized Controlled Study

NCT07539779 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT07539779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07539779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Luspatercept in Preventing Poor Erythroid Engraftment After Allo-HSCT for Hematological Malignancies With Moderate to Severe Myelofibrosis: A Prospective, Multicenter, Randomized Controlled Study
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
December 31, 2030
Enrollment
196 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancies, luspatercept, myelofibrosis (mf), poor erythroid engraftment